• Is FDA slowing down the progress in clinical cell therapy?
    This question is currently highly discussed in professional communities. Professionals think that too strict or/ and unclear regulation system is one of the main hurdles in translation of cell therapy and stem cell research into the clinic. The FDA is a regulatory agency which approves the use of biological products (including cells) and drugs for medical use in US. Even though the FDA has a set of rules for cell products in place, in some cases there is still misunderstanding [...]
  • Conditional cell immortalization using ROCK-inhibitor

    by Alexey Bersenev January 15, 2012 methods

    Maintaining the primary cells in culture sometimes is very difficult task. Some normal and malignant cells types just don’t grow well in culture. It makes very difficult cell-based diagnostics and therapy development. Recently, the group of researchers proposed the method, which allows to overcome this problem. They called it “conditional immortalization”. From Science Daily: “We tried breast cells and they grew well. We tried prostate cells and their growth was fantastic, which is amazing because it is normally impossible to [...]

    0 comments Read the full article →

    Series of retractions from Amy Wagers’ stem cell lab

    by Alexey Bersenev January 11, 2012 notes

    We wrote about some “high profile” paper retractions in stem cell field. Unfortunately, very recently, we’ve got more retractions from Amy Wagers lab at Harvard Stem Cell Institute. I think, it’s important to follow-up on this case, because her studies had a significant impact in the field. In 2010, Nature retracted Wagers paper about rejuvenation of blood stem cell niches. The whole chain reaction of events has followed later: Blood posts “notice of concern” over second Wagers-Mayack paper Editor of [...]

    0 comments Read the full article →

    Support Sabrina Cohen Foundation!

    by Alexey Bersenev January 10, 2012 notes

    I’m always amazed by enthusiasm of patient’s advocates, especially by those with tragic personal stories. Among them, the brightest advocates of stem cell research – Christopher Reeve, Roman Reed and Sabrina Cohen. Sabrina Cohen is a great supporter and advocate of stem cell research. She endured spinal cord injury from a car accident when she was a teenager. In 2006 she created Sabrina Cohen Foundation to educate a public about stem cells and raise funds for research. Up to date, [...]

    0 comments Read the full article →

    Public cell therapy and stem cell companies in 2011

    by Alexey Bersenev January 8, 2012 RegenMed digest

    Today, I’d like to look at how well public cell therapy and stem cell companies were doing on the market in 2011. By analyzing data, available for public, we can learn about trust and investor confidence in the sector. We can track stock market charts and quarterly earnings reports. First, I’d like to look at stock market charts. I’ve picked the most interesting companies (n=22) to watch and embedded charts from Dec. 31, 2010 to Dec. 30, 2011 time period. [...]

    3 comments Read the full article →

    Genomic stability of clinical-grade mesenchymal stromal cells – a proposal for international initiative

    by Alexey Bersenev January 5, 2012 cell product

    The discussion about genomic stability of mesenchymal stromal cells (MSC) is still continuing. We wrote about the importance of this here and here. In today’s issue of Cell Stem Cell journal there are two commentaries to Ben-David’s article about this issue. The one says – no, the problem is overblown, the other says – yes, the problem is here. The authors made a good arguments from both sides. It seems to me that both sides agree on monitoring genomic stability [...]

    1 comment Read the full article →

    Crackdown on “stem cell treatment” fraud in US

    by Alexey Bersenev January 4, 2012 notes

    The recent FBI indictments in “stem cell therapy” fraud caused a big buzz in professional community. I’d like to link to some opinions: American scientist arrested in stem-cell clinic sting (Nature news) My message to dubious stem cell clinics and facilitators: now would be a very good time to shutdown (Knoepfler Lab Stem Cell Blog) Dr. Frank gets cell therapy (Stem Cell Treatment Monitor) For me, the most interesting part was about “American scientist”. From FBI release: The stem cells [...]

    1 comment Read the full article →

    Method of the year 2011 – Targeted genome editing by zinc finger nucleases

    by Alexey Bersenev January 2, 2012 methods

    Every year, right after New Year holidays, we are picking the most significant and interesting methods of the year. The winner of 2011 – targeted genome editing by zinc finger nucleases. Few major advances in using zinc finger nucleases (ZNF) technology were made in 2011. First of all, the usability of this technology in clinic was demonstrated in HIV cell therapy trial. Tthe first preliminary results of Sangamo‘s HIV clinical trial were reported. They use ZNF technology (targenig CCR5) in [...]

    0 comments Read the full article →

    Stem Cell Assays in 2011

    by Alexey Bersenev December 31, 2011 notes

    It was very interesting year for us and, I hope, for you too. Today we are going to look back at 2011 and share some thoughts and site statistics. This year we had 37 000 visits (including 24 000 unique visitors) and 64 000 pageviews. It’s much greater than 2010 statistics. Some of you prefer to read us via RSS or e-mail. We have 165 regular subscribers now. The most popular posts in 2011: 1. Counting cells with hemocytometer – [...]

    1 comment Read the full article →

    Regenerative medicine and cell therapy industry in 2011

    by Alexey Bersenev December 29, 2011 RegenMed digest

    At the end of the year I’d like to overview the most notable events in cell therapy and regenerative medicine industry. What made the headlines in mass media? What events were highly discussed in professional communities? It was very eventful year, but I’ve picked 10, most important in my opinion. 1. Geron ended stem cell programs It was the most discussed news this year. Big hope for a spinal cord injury trial, big loss for a field. Many professionals noted [...]

    2 comments Read the full article →

    Top stem cell papers in 2011 by Faculty of 1000

    by Alexey Bersenev December 27, 2011 notes

    In the next 2 weeks we will share and discuss the results of the year 2011. The most significant discoveries in stem cell research, the most notable events in cell therapy. Don’t miss it! I continue to share the most highly ranked articles in stem cell research by Faculty Members of post-publication peer review platform Faculty of 1000. Today, I’m sharing the most highly ranked stem cell papers of 2011. Once again, the articles ranked by Faculty Members according F1000 [...]

    0 comments Read the full article →